Completed NA INTERVENTIONAL NCT00416390

Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia

The Effect of Lycopene on DNA Damage in Human Prostate

Sponsor: National Cancer Institute (NCI)

Conditions Nonmalignant Neoplasm Prostate Cancer

Interventions biopsy laboratory biomarker analysis lycopene

Updated 5 times since 2017 Last updated: Sep 19, 2013 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00416390, this NA trial focuses on Nonmalignant Neoplasm and Prostate Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Illinois at Chicago

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.